鼻咽頭炎(風邪)(Nasopharyngitis (Common Cold))の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nasopharyngitis (Common Cold) Overview 7
Therapeutics Development 8
Pipeline Products for Nasopharyngitis (Common Cold) – Overview 8
Pipeline Products for Nasopharyngitis (Common Cold) – Comparative Analysis 9
Nasopharyngitis (Common Cold) – Therapeutics under Development by Companies 10
Nasopharyngitis (Common Cold) – Therapeutics under Investigation by Universities/Institutes 11
Nasopharyngitis (Common Cold) – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Nasopharyngitis (Common Cold) – Products under Development by Companies 15
Nasopharyngitis (Common Cold) – Products under Investigation by Universities/Institutes 16
Nasopharyngitis (Common Cold) – Companies Involved in Therapeutics Development 17
Cocrystal Pharma, Inc. 17
Neos Therapeutics, Inc. 18
Orbis Biosciences, Inc. 19
Vernalis plc 20
Nasopharyngitis (Common Cold) – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 28
Drug Profiles 30
(chlorpheniramine + codeine) – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CCP-01 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CCP-05 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CCP-06 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CCP-07 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CCP-08 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
guaifenesin ER – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule for Cough and Cold – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Inhibit MAPK13 for Asthma and Cold – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Nasopharyngitis (Common Cold) – Recent Pipeline Updates 42
Nasopharyngitis (Common Cold) – Dormant Projects 44
Nasopharyngitis (Common Cold) – Discontinued Products 45
Nasopharyngitis (Common Cold) – Product Development Milestones 46
Featured News & Press Releases 46
Sep 15, 2014: FDA accepts Tuzistra XR (CCP-01) NDA for full review 46
Jul 22, 2014: Third Product in Vernalis’ Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 46
Feb 24, 2014: Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01 46
Nov 25, 2013: Vernalis Announces Successful Pivotal Single Dose Bioavailability Study with First Cough Cold Product, CCP-01 47
Mar 06, 2013: Vernalis’s First Product In Cough Cold Pipeline Achieves Proof-of-concept 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49